Literature DB >> 23016856

microRNA biogenesis pathway as a therapeutic target for human disease and cancer.

Francesca De Santa1, Ilaria Iosue, Alberto Del Rio, Francesco Fazi.   

Abstract

The deregulation of microRNAs expression and activity is frequently observed in a wide variety of human pathologies including cancer. Accordingly, growing evidence indicates that the targeting of microRNAs biogenesis and pathways is emerging as a central tool for the development of novel RNA-based drugs and therapies to defeat diseases in humans. In this review we describe the various strategies that can be used to target microRNAs and specific RNA-binding proteins, involved in the regulation of their production, localization, stability and activity, in human cancer and cardiovascular diseases. We also focus on the efforts that are currently made to enhance the potency and stability of these therapeutic agents and their delivery to modulate in vivo microRNAs pathways. Finally, we present structural data on proteins that belong to the microRNA pathway for small molecules-based target therapy design.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23016856

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  16 in total

1.  Upregulation of miR-195 enhances the radiosensitivity of breast cancer cells through the inhibition of BCL-2.

Authors:  Jian Zhu; Qing Ye; Li Chang; Wei Xiong; Qingqing He; Wenhui Li
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis.

Authors:  Chuan-Feng Huang; Cheng-Chao Sun; Fang Zhao; Ya-Dong Zhang; De-Jia Li
Journal:  J Gastroenterol       Date:  2014-08-26       Impact factor: 7.527

3.  Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry.

Authors:  Frank Qian; Ye Feng; Yonglan Zheng; Temidayo O Ogundiran; Oladosu Ojengbede; Wei Zheng; William Blot; Christine B Ambrosone; Esther M John; Leslie Bernstein; Jennifer J Hu; Regina G Ziegler; Sarah Nyante; Elisa V Bandera; Sue A Ingles; Michael F Press; Katherine L Nathanson; Anselm Hennis; Barbara Nemesure; Stefan Ambs; Laurence N Kolonel; Olufunmilayo I Olopade; Christopher A Haiman; Dezheng Huo
Journal:  Hum Genet       Date:  2016-07-05       Impact factor: 4.132

Review 4.  The Effect of miRNA Gene Regulation on HIV Disease.

Authors:  Romona Chinniah; Theolan Adimulam; Louansha Nandlal; Thilona Arumugam; Veron Ramsuran
Journal:  Front Genet       Date:  2022-05-04       Impact factor: 4.772

5.  Dysregulation of microRNA biosynthesis enzyme Dicer plays an important role in gastric cancer progression.

Authors:  Jin Zhang; Xin-Hua Zhang; Cai-Xia Wang; Biao Liu; Xiang-Shan Fan; Juan-Juan Wen; Qun-Li Shi; Xiao-Jun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 6.  Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

Authors:  Federico Andreoli; Arménio Jorge Moura Barbosa; Marco Daniele Parenti; Alberto Del Rio
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.310

Review 7.  Computer-aided Molecular Design of Compounds Targeting Histone Modifying Enzymes.

Authors:  Federico Andreoli; Alberto Del Rio
Journal:  Comput Struct Biotechnol J       Date:  2015-05-07       Impact factor: 7.271

8.  MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer.

Authors:  Qifeng Luo; Chuankui Wei; Xiaoyu Li; Jia Li; Lei Chen; Yixiang Huang; Hongming Song; Dengfeng Li; Lin Fang
Journal:  Oncol Rep       Date:  2014-01-08       Impact factor: 3.906

Review 9.  MicroRNA-143/-145 in Cardiovascular Diseases.

Authors:  Wang Zhao; Shui-Ping Zhao; Yu-Hong Zhao
Journal:  Biomed Res Int       Date:  2015-06-28       Impact factor: 3.411

10.  ERManI is a target of miR-125b and promotes transformation phenotypes in hepatocellular carcinoma (HCC).

Authors:  Shujuan Pan; Xiaoyun Cheng; Hongan Chen; Patricia D Castro; Michael M Ittmann; Anne W Hutson; Susan K Zapata; Richard N Sifers
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.